Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (921)	2/5/2002 8:31:35 PM
From: aknahow	Read Replies (1) \| Respond to of 2243

BGEN/ELN terms seem straight forward. In August 2000, the Company signed a development and marketing collaboration agreement (the "Antegren Agreement") with Elan Corporation, plc ("Elan") under which the Company and Elan collaborate in the development, manufacture and commercialization of Antegren(R), a humanized monoclonal antibody and alpha 4 integrin inhibitor. Under the terms of the Antegren Agreement, Biogen and Elan will share costs for on-going development activities. The Company paid a one-time non-refundable license fee of $15 million, which was charged to research and development expense.